# Tim Funnell

> Tim Funnell is a London-based British investor and company builder, co-founder and partner at Monograph Capital. He co-founded MiroBio and served as its VP of Operations, was Ascend Advanced Therapies’ founding CEO and is now an Ascend director. He also helped establish OUTbio UK and has advised laboratory property developer Mission Street.

- **Role:** Co-founder and Partner at Monograph Capital; Director at Ascend Advanced Therapies
- **Organizations:** Monograph Capital, Ascend Advanced Therapies, MiroBio, OUTbio UK, Mission Street, Syncona, Third Rock Ventures, Oxford Science Enterprises, Boston Consulting Group, Elevara Medicines, Ouro Medicines, RQ Biotechnology Holdings, Maxion Therapeutics
- **Nationality:** British
- **Education:** Undergraduate degree; pharmacology training, University of Cambridge, DPhil, Pharmacology, University of Oxford
- **Known for:** Co-founded MiroBio and served as VP of Operations before its acquisition by Gilead., Co-founded Monograph Capital in 2021., Served as Ascend’s founding CEO and helped assemble the business before its 2023 public launch with $132.5 million in total funding.

## Career timeline

- **2011–2013** — Consultant at Boston Consulting Group in London.
- **2013–2016** — Worked at Syncona on investment and company building.
- **2017** — Principal at Third Rock Ventures in Boston.
- **2018–2021** — Founding team member and VP of Operations at MiroBio; the company publicly launched in 2019.
- **2020** — Became an OUTbio UK director on 14 October.
- **2021** — Co-founded Monograph Capital; appointed LLP member on 9 June.
- **2022** — Gilead announced the MiroBio acquisition at approximately $405 million; completed on 20 September at $414 million in cash.
- **2023** — Joined Mission Street’s advisory board; Ascend launched publicly, with Mike Stella succeeding founding CEO Funnell.
- **2025** — Named to Elevara Medicines’ board at its October launch.
- **2026** — Ouro Medicines acquisition completed in June; became a director of RQ Biotechnology Holdings on 17 June.

## Achievements

- Co-founded MiroBio and served as VP of Operations before its acquisition by Gilead.
- Co-founded Monograph Capital in 2021.
- Served as Ascend’s founding CEO and helped assemble the business before its 2023 public launch with $132.5 million in total funding.
- Helped establish OUTbio UK, the first international affiliate of the Boston-founded network.

## Latest updates

- **2026-06** — Ouro Medicines acquisition completed on 4 June: $1.675 billion upfront plus up to $500 million in contingent milestone payments, shared equally by Gilead and Lakefront.
- **2026-06** — Appointed director of RQ Biotechnology Holdings on 17 June.
- **2025-10** — Named to the board at Elevara Medicines’ launch.

## Links

- LinkedIn: https://www.linkedin.com/in/tim-funnell/

---

Profile page: https://yespress.io/tim-funnell
Published by YesPress — https://yespress.io
Last updated: 2026-10-23